Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: A systematic review and meta-analysis

---

Authors

Carlos Taxonera¹ , David Olivares¹

1. Hospital Clinico San Carlos, Madrid, Spain

Conference / event

Digestive Disease Week 2023, May 2023 (Chicago, United States)

Poster summary

A systematic search was conducted in electronic databases for observational studies evaluating ustekinumab for UC. Of 254 citations, 19 studies were included with 3786 patients. Clinical remission was achieved in 45.4% of patients at week 8, 43.8% at weeks 12 to 16, 44.6% at month 6, and 50.6% at month 12. Corticosteroid-free remission was achieved in 18.7%, 36.8%, 34.5%, and 39% of patients at week 8, weeks 12 to 16, month 6, and month 12, respectively. Endoscopic improvement was achieved in 29.9%, 24.3%, and 58.2% of patients at weeks 12 to 16, month 6, and month 12, respectively. The IRs of colectomy, AE, serious AE, and serious infections were 4.8, 7.9, 0.8 and 0.3 per 100 PY, respectively. The results of this meta-analysis of observational studies confirm the effectiveness of ustekinumab in UC. The acceptable safety data support the positive long-term benefit-risk profile of ustekinumab for UC.

Keywords

Ustekinumab, Ulcerative colitis, Real-world evidence, Systematic review, Meta-analysis

Research areas

Medicine

References

No data provided

Funding

No data provided

Supplemental files

No data provided

Additional information

Competing interests

No competing interests were disclosed.

Data availability statement

The datasets generated during and / or analyzed during the current study are available from the corresponding author on reasonable request.

Creative Commons license

Copyright © 2023 Taxonera et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.